Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Graham Vioxx study

This article was originally published in The Tan Sheet

Executive Summary

"Patients taking Vioxx had a 34% higher chance of coronary heart disease when compared with people who used other NSAIDs," David Graham, MD, FDA Office of Drug Safety, et al., conclude in a study published online by The Lancet Jan. 25. The study indicated Merck's Vioxx may have caused 88,000-140,000 excess cases of coronary heart disease since its launch. Researchers analyzed data on 1.4 mil. people who used either rofecoxib, celecoxib, ibuprofen or naproxen from January 1999 through December 2001. Participants who took naproxen experienced a 14% increased risk of coronary heart disease compared to those using other NSAIDs. "Because of limited power, we were unable to fully address whether the cardiovascular risk associated with rofecoxib varied by duration of use," Graham et al. note...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel